Structured nutritional management of insulin resistance in women with PMOS (formerly PCOS) receiving GLP-1RA therapy.
文献摘要
Polyendocrine Metabolic Ovarian Syndrome (PMOS, formerly PCOS) is the most prevalent endocrine disorder in reproductive-age women, with insulin resistance central to its pathophysiology. GLP-1 receptor agonists (GLP-1RAs) improve weight and reproductive outcomes in PMOS, but their effect on the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) remains inconsistent, and no structured nutrition protocol accompanies their use. This review evaluated GLP-1RA efficacy in PMOS through a structured review of PubMed, Google Scholar and major clinical guidelines, and proposes a nutrition protocol targeting metabolic-insulin homeostasis. GLP-1RAs produced consistent reductions in weight, androgens and fasting insulin, but HOMA-IR outcomes remained heterogeneous across trials, with gains reversing after treatment withdrawal. This inconsistency was linked to an under-recognised nutritional consequence of appetite suppression - inadequate protein intake and progressive micronutrient depletion - compounding pre-existing PMOS-specific deficits. A structured three-phase clinical nutrition protocol is proposed, targeting protein optimisation, micronutrient repletion and resistance exercise alongside GLP-1RA therapy. This is not weight-centric care. It is metabolic restoration-focused care - encompassing HOMA-IR trajectory, lean mass and micronutrient status together - supporting a role for the clinical nutritionist within GLP-1RA prescribing pathways for women with PMOS.